XLV

2019: Another Market Beating Year for the Best Ideas Newsletter Portfolio!

by

2019: Another Market Beating Year for the Best Ideas Newsletter Portfolio! — Summary: — We estimate thus far the Best Ideas Newsletter portfolio return has beat the S&P 500 by 2.8 percentage points during 2019 (34.4% versus 31.6% for the S&P 500, as measured by the SPY). — Our move to overweight Apple, Facebook, and Visa worked out wonderfully for members during 2019. We continue to overweight big winners, and we credit this to our team’s conviction in our very best ideas. —  We also made quite the savvy move in rolling over a solid gain in Chipotle (60%+) into even more shares of Apple stock during the year. We’re putting some of the best ideas right in front of … Read more

Health Care Sector Remains Hot

by

Image Shown: The Health Care Select Sector SPDR ETF, a holding in both our Best Ideas Newsletter and Dividend Growth Newsletter portfolios, has been on an upward tear over the past several years. Strong macro tailwinds combined with the ability for industries within the health care sector to generate meaningful shareholder value have been key to supporting strong capital appreciation of equities operating in the area of late. By Callum Turcan The Health Care Select Sector SPDR ETF (XLV) is a top holding in both our Best Ideas Newsletter and Dividend Growth Newsletter portfolios. We like the exposure and diversification to health care equities that XLV provides. XLV yields ~1.5% as of this writing. State Street Corp (STT) acts as … Read more

More Big Pharma Earnings to Digest

by

Image Source: Zoetis Inc – 2019 Annual Shareholders Meeting Presentation Calendar third-quarter 2019 earnings was a busy time for biotech and pharma companies. We covered a number of biotech and pharma earnings in this piece here, but let’s dig into a few others. In alphabetical order by ticker: GSK, PFE, ZTS. By Callum Turcan In alphabetical order by ticker: GSK, PFE, ZTS GlaxoSmithKline plc (GSK)–4.6% yield–reported third quarter results for 2019 on October 30. Its pro forma adjusted sales rose by 6% year-over-year, and please note the British pharmaceutical and consumer health giant has been very busy over the past couple of years. Before we get into that, note GlaxoSmithKline reported strong performance across the board at its three main … Read more

Our Reports on Stocks in the Pharmaceuticals – Big Industry

by

Image Source: A 4 Structure of the Pharmaceuticals – Big Industry The big pharma industry is primarily composed of makers of branded drugs. Intellectual property protection is vital to the successful commercialization of medicines and offers makers of branded drugs a unique competitive advantage via patents, which can extend for decades. When branded drugs lose market exclusivity, however, makers of generic pharmaceuticals can generate intense price competition, causing drastic revenue losses on unprotected therapies. Long-term success for branded pharma companies depends on a strong and diverse drug pipeline, which can be augmented by M&A activity. We generally like the group and expect continued industry consolidation. We’ve optimized our health care coverage, the reports of which can be found here.

Biotech and Pharma Roundup

by

Image Source: e-Magine Art Some big news in the world of biotech and pharmaceuticals has come out this week, starting Monday October 21, that we want to get out in front of our members. In alphabetical order by ticker symbol: BIIB, BMY, MRK, NVS. By Callum Turcan Biogen Inc (BIIB) reported third quarter 2019 earnings on Tuesday October 22 that easily beat both top and bottom line estimates. That was partially due to strong sales at its SPINRAZA offering, which is used to treat spinal muscular atrophy. Shares of BIIB rocketed higher during the trading session as investors priced in the upside that Biogen’s Aducanumab treatment could generate, with the company announcing that it was going to ask the US … Read more

Johnson & Johnson Raises Full-Year Guidance Yet Again

by

Image Shown: Shares of Johnson & Johnson climbed higher on October 15 after reporting a nice third quarter earnings report and raising guidance for the full year. By Callum Turcan On October 15, Best Ideas Newsletter and Dividend Growth Newsletter holding Johnson & Johnson (JNJ) reported third-quarter 2019 earnings that were positively received by the market. The healthcare giant once again boosted full-year non-GAAP sales and EPS guidance, which we appreciate, on the back of solid performance at its ‘Pharmaceuticals’ and ‘Medical Devices’ segments. Please note that Johnson & Johnson had already raised its guidance for 2019 twice before this latest increase, which we covered in this July 2019 piece here and this April 2019 piece here. During the third … Read more

Economic Commentary: Robots, Value Trap, and Politics on the Markets

by

Tickerized for stocks in the DIA. Valuentum sat down for the latest installment of its periodic economic commentary, and the team tackled a wide array of topics, from robots on Wall Street, to President of Investment Research Brian Nelson’s new book Value Trap, to political influence on the markets and boyond. Let’s set the stage with a prompt from a recent Bloomberg article, “The Master of Robots…Coming for Wall Street:” “The problem is, computer-powered strategies are struggling to live up to the hype, with a Eurekahedge index of AI hedge funds lagging peers in recent years. That spells opportunity for the likes of Lopez de Prado with his outfit True Positive Technologies — a dig at the erroneous conclusions derived … Read more

Competition Heats Up in the Medical Robotics Space

by

Image Source: Intuitive Surgical Inc – IR Presentation Competition is heating up in the medical robotics space, an area of the medical device industry Intuitive Surgical (ISRG) is a clear leader in with its Da Vinci system installed in ~5,000 hospitals and other medical centers around the world (approximately 60% of Intuitive Surgical’s installed base is in the US). Intuitive Surgical’s business model is built around charging healthcare providers an upfront fee along with additional charges for single use instruments which creates strong reoccurring revenue streams. The Da Vinci system is a robot-assisted surgical device that has been shown to meaningfully improve patient outcomes, seen through lower levels of blood loss and shorter hospital stays across multiple different types of … Read more

The Orthodontics Industry Is Getting Disrupted

by

Image Source: SmileDirectClub Inc – S-1 SEC Filing By Callum Turcan SmileDirectClub (SDC), the teledentistry startup that makes 3D-printed clear aligners which are a cheaper alternative to braces (albeit with drawbacks when compared to the traditional braces route), went public this September at $23/share. The stock has come under pressure since then over concerns regarding its mounting losses. What makes SmileDirectClub different than traditional orthodontics practices is that customers don’t necessarily need to go into an office to get these types of services. The company has its SmileShops where customer’s teeth can be scanned in-store within half an hour, or offers remote impression kits that are shipped to the customer’s house and then shipped back. Another important consideration is that … Read more

Merck Shows Impressive Margin Expansion

by

Image Source: Merck & Co Inc – IR Presentation By Callum Turcan Pharmaceutical giant Merck (MRK) has performed well during the past few fiscal years by reducing operating costs while utilizing strong growth at some of its oncology drug offerings to drive sales higher. Shares of Merck yield 2.7% as of this writing and are trading at the upper half of our fair value estimate range after an impressive run up in Merck’s stock price began in April 2018. Management recently raised Merck’s full-year sales and non-GAAP EPS guidance for 2019, which we will cover in a moment. Enhancing Profitability Levels From 2016 to 2018, Merck cut its GAAP operating expenses from $35.1 billion to $33.6 billion (down over 4%) … Read more